Assessment of FIV-C infection of cats as a function of treatment with the protease inhibitor, TL-3

Retrovirology

Volumn 1, Issue , 2004, Pages

  de Rozières, Sohela ^a   Swan, Christina H ^a   Sheeter, Dennis A ^a   Clingerman, Karen J ^a   Lin, Ying Chuan ^a   Huitron Resendiz, Salvador ^a   Henriksen, Steven ^a   Torbett, Bruce E ^a   Elder, John H ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; PROTEINASE; PROTEINASE INHIBITOR; TL 3; UNCLASSIFIED DRUG;

ACUTE PHASE RESPONSE; ANIMAL EUTHANASIA; ANIMAL EXPERIMENT; ANTIBIOTIC RESISTANCE; ANTIVIRAL ACTIVITY; ARTICLE; CAT; CAT DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; FELINE IMMUNODEFICIENCY VIRUS; FEMALE; GENETIC VARIABILITY; IMMUNE DEFICIENCY; IMMUNE STATUS; LYMPHOCYTE COUNT; MONITORING; MONOTHERAPY; MORTALITY; NONHUMAN; SURVIVAL RATE; SYMPTOMATOLOGY; VIREMIA; VIRUS DETECTION; VIRUS LOAD; VIRUS MUTANT; WILD TYPE; ANIMAL; BRAIN STEM; COHORT ANALYSIS; DISEASE TRANSMISSION; DRUG EFFECT; EVOKED AUDITORY RESPONSE; FELINE ACQUIRED IMMUNODEFICIENCY SYNDROME; ISOLATION AND PURIFICATION; PATHOGENICITY; PATHOPHYSIOLOGY; PHYSIOLOGY; WEIGHT REDUCTION;

ANIMALS; BRAIN STEM; CATS; COHORT STUDIES; EVOKED POTENTIALS, AUDITORY; FELINE ACQUIRED IMMUNODEFICIENCY SYNDROME; FEMALE; IMMUNODEFICIENCY VIRUS, FELINE; PROTEASE INHIBITORS; VIRAL LOAD; WEIGHT LOSS;

EID: 18144389472     PISSN: 17424690     EISSN: None     Source Type: Journal    
DOI: 10.1186/1742-4690-1-38     Document Type: Article

References (25)

1. Diehl LJ, Mathiason-Dubard CK, O'Neil LL, Obert LA, Hoover EA: Induction of accelerated feline immunodeficiency virus disease by acute-phase virus passage. J Virol 1995, 69:6149-6157.
2. Sparger EE, Beebe AM, Dua N, Himathongkam S, Elder JH, Torten M, Higgins J: Infection of cats with molecularly cloned and biological isolates of the feline immunodeficiency virus. Virology 1994, 205:546-553.
3. Pedersen NC, Leutenegger CM, Woo J, Higgins J: Virulence differences between two field isolates of feline immunodeficiency virus (FIV-APetaluma and FIV-CPGammar) in young adult specific pathogen free cats. Vet Immunol Immunopathol 2001, 79:53-67.
4. de Monte M, Nonnenmacher H, Brignon N, Ullmann M, Martin JP: A multivariate statistical analysis to follow the course of disease after infection of cats with different strains of the feline immunodeficiency virus (FIV). J Virol Methods 2002, 103: 157-170.
5. Collier AC, Coombs RW, Schoenfeld DA, Bassett RL, Timpone J, Baruch A, Jones M, Facey K, Whitacre C, McAuliffe VJ, Friedman HM, Merigan TC, Reichman RC, Hooper C, Corey L: Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N Engl J Med 1996, 334:1011-1017.
6. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, Richman DD, Valentine FT, Jonas L, Meibohm A, Emini EA, Chodakewitz JA: Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997, 337:734-739.
7. Palella FJJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998, 338: 853-860.
8. Kirk O, Katzenstein TL, Gerstoft J, Mathiesen L, Nielsen H, Pedersen C, Lundgren JD: Combination therapy containing ritonavir plus saquinavir has superior short-term antiretroviral efficacy: a randomized trial. AIDS 1999, 13:F9-16.
9. McMichael AJ, Phillips RE: Escape of human immunodeficiency virus from immune control. Annu Rev Immunol 1997, 15:271-296.
10. Elder JH, Schnolzer M, Hasselkus-Light CS, Henson M, Lerner DA, Phillips TR, Wagaman PC, Kent SB: Identification of proteolytic processing sites within the Gag and Pol polyproteins of feline immunodeficiency virus. J Virol 1993, 67:1869-1876.
11. Schnolzer M, Rackwitz HR, Gustchina A, Laco GS, Wlodawer A, Elder JH, Kent SB: Comparative properties of feline immunodeficiency virus (FIV) and human immunodeficiency virus type 1 (HIV-1) proteinases prepared by total chemical synthesis. Virology 1996, 224: 268-275.
12. Lee T, Laco GS, Torbett BE, Fox HS, Lerner DL, Elder JH, Wong CH: Analysis of the S3 and S3′ subsite specificities of feline immunodeficiency virus (FIV) protease: development of a broad-based protease inhibitor efficacious against FIV, SIV, and HIV in vitro and ex vivo. Proc Natl Acad Sci U S A 1998, 95:939-944.
13. Huitron-Resendiz S, De Rozieres S, Sanchez-Alavez M, Buhler B, Lin YC, Lerner DL, Henriksen NW, Burudi M, Fox HS, Torbett BE, Henriksen S, Elder JH: Resolution and Prevention of Feline Immunodeficiency Virus-Induced Neurological Deficits by Treatment with the Protease Inhibitor TL-3. J Virol 2004, 78:4525-4532.
14. Phillips TR, Prospero-Garcia O, Wheeler DW, Wagaman PC, Lerner DL, Fox HS, Whalen LR, Bloom FE, Elder JH, Henriksen SJ: Neurologic dysfunctions caused by a molecular clone of feline immunodeficiency virus, FIV-PPR. J Neurovirol 1996, 2: 388-396.
15. Laco GS, Schalk-Hihi C, Lubkowski J, Morris G, Zdanov A, Olson A, Elder JH, Wlodawer A, Gustchina A: Crystal structures of the inactive D30N mutant of feline immunodeficiency virus protease complexed with a substrate and an inhibitor. Biochemistry 1997, 36: 10696-10708.
16. Beck ZQ, Lin YC, Elder JH: Molecular basis for the relative substrate specificity of human immunodeficiency virus type 1 and feline immunodeficiency virus proteases. J Virol 2001, 75: 9458-9469.
17. Walker C, Canfield PJ, Love DN: Analysis of leucocytes and lymphocyte subsets for different clinical stages of naturally acquired feline immunodeficiency virus infection. Vet Immunol Immunopathol 1994, 44:1-12.
18. Hofmann-Lehmann R, Holznagel E, Aubert A, Bauer-Pham K, Lutz H: FIV vaccine studies. II. Clinical findings, hematological changes and kinetics of blood lymphocyte subsets. Vet Immunol Immunopathol 1995, 46:115-125.
19. Hawkins EC, Kennedy-Stoskopf S, Levy JK, Meuten DJ, Cullins L, Tompkins WA, Tompkins MB: Effect of FIV infection on lung inflammatory cell populations recovered by bronchoalveolar lavage. Vet Immunol Immunopathol 1996, 51:21-28.
20. Coffin JM: HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995, 267:483-489.
21. Condra JH, Schleif WA, Blahy OM, Gabryelski LJ, Graham DJ, Quintero JC, Rhodes A, Robbins HL, Roth E, Shivaprakash M, Titus D, Yang T, Tepplert H, Squires KE, Deutsch PJ, Emini EA: In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995, 374:569-571.
22. Wlodawer A, Gustchina A, Reshetnikova L, Lubkowski J, Zdanov A, Hui KY, Angleton EL, Farmerie WG, Goodenow MM, Bhatt D, Zhang L, Dunn B: Structure of an inhibitor complex of the proteinase from feline immunodeficiency virus. Nat Struct Biol 1995, 2:480-488.
23. Gong YF, Robinson BS, Rose RE, Deminie C, Spicer TP, Stock D, Colonno RJ, Lin PF: In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632. Antimicrob Agents Chemother 2000, 44:2319-2326.
24. Buhler B, Lin YC, Morris G, Olson AJ, Wong CH, Richman DD, Elder JH, Torbett BE: Viral evolution in response to the broad-based retroviral protease inhibitor TL-3. J Virol 2001, 75: 9502-9508.
25. Diehl LJ, Mathiason-Dubard CK, O'Neil LL, Hoover EA: Plasma viral RNA load predicts disease progression in accelerated feline immunodeficiency virus infection. J Virol 1996, 70: 2503-2507.